MedTrace Logo

EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture

NCT03955458 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-02-27

No results posted yet for this study

Summary

This study evaluates the effect of EXPAREL on total opioid consumption through 72 hours following fascia iliaca compartment block (FICB) in subjects undergoing repair of intertrochanteric hip fracture.

Conditions

  • Hip Fractures
  • Intertrochanteric Fractures

Interventions

DRUG

EXPAREL

FICB with EXPAREL + Bupivacaine HCL (single dose)

DRUG

Ropivacaine

FICB with continuous infusion of ropivacaine

DRUG

Bupivacaine Hydrochloride

FICB with EXPAREL + Bupivacaine HCL (Single dose)

Sponsors & Collaborators

  • Pacira Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Nayana Nagaraj, MD, PhD, MPH · Pacira Biosciences Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2020-05-31
Completion
2020-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03955458 on ClinicalTrials.gov